Nonlinear Pharmacokinetics Study Guide

Introduction to Nonlinear Pharmacokinetics

• General Concept of Linear Pharmacokinetics:     * In most cases, at therapeutic doses, the change in the amount of drug in the body or the change in its plasma concentration due to absorption, distribution, binding, metabolism, or excretion is proportional to the dose.     * This proportionality applies whether the drug is administered as a single dose or as multiple doses.     * First-Order Kinetics: When rate processes are proportional to the dose, they are said to follow first-order or linear kinetics.     * Principle of Superposition: All semilog plots of concentration ($C$) versus time ($t$) for different doses, when corrected for the dose administered, are superimposable. This is the underlying principle for linear systems.     * Dose-Independent Parameters: The important pharmacokinetic parameters such as fraction bioavailable ($F$), absorption rate constant ($K_a$), elimination rate constant ($K_E$), apparent volume of distribution ($V_d$), renal clearance ($Cl_R$), and total systemic clearance ($Cl$) remain unaffected by the dose.

• Concept of Nonlinear Pharmacokinetics:     * Nonlinearity occurs when the rate processes of a drug's ADME (Absorption, Distribution, Metabolism, and Excretion) are dependent upon carriers or enzymes that are substrate-specific.     * These carriers/enzymes have definite capacities and are susceptible to saturation at high drug concentrations.     * Kinetic Transformation: In these cases, essentially first-order kinetics transform into a mixture of first-order and zero-order rate processes.     * Dose-Dependent Parameters: Pharmacokinetic parameters change with the size of the administered dose.     * Synonymous Terms: Nonlinear pharmacokinetics is also referred to as:         * Dose-dependent kinetics.         * Mixed-order kinetics.         * Capacity-limited kinetics.     * Graphical Representation: A plot of the amount of drug in tissue ($mg/kg$) versus dose size ($mg/kg$) shows a straight line for linear pharmacokinetics, while nonlinear pharmacokinetics exhibits a curve that deviates from that straight line as the dose increases.

Detection of Nonlinearity in Pharmacokinetics

• Simplest Detection Methods:     1. Steady-State Plasma Concentration ($C_{ss}$): Determination of $C_{ss}$ at different doses. If $C_{ss}$ values are directly proportional to the dose, linearity exists. Proportionality is absent in nonlinear kinetics.     2. Pharmacokinetic Parameters: Determination of parameters such as fraction bioavailable ($F$), elimination half-life ($t_{1/2}$), or total systemic clearance ($Cl$) at different doses. Any change in these usually constant parameters indicates nonlinearity.

• Steady-State Characteristics:     * Steady-state is attained after approximately four half-times ($4 \times t_{1/2}$).     * The time required to reach steady-state is independent of the dosage.

Causes of Nonlinearity in Pharmacokinetics

Drug Absorption

Nonlinearity in absorption arises from three primary sources:

1. Solubility or Dissolution Rate-Limited Absorption:     * Example: Griseofulvin.     * At higher doses, a saturated solution of the drug is formed in the Gastrointestinal Tract (GIT) or other extravascular sites. The rate of absorption then reaches a constant value.

2. Carrier-Mediated Transport Systems:     * Examples: Riboflavin, ascorbic acid, cyanocobalamin (vitamins).     * Saturation of the transport system at higher doses results in nonlinearity.

3. Presystemic Gut Wall or Hepatic Metabolism:     * Examples: Propranolol, hydralazine, and verapamil.     * Saturation of enzymes during the first pass (presystemic metabolism) at high doses leads to increased bioavailability ($F$).

• Affected Parameters in Absorption: Parameters like $F$, $K_a$, $C_{max}$, and $AUC$ are impacted. A decrease in these is seen in solubility/carrier-limited cases, while an increase is seen when presystemic metabolism is saturated.

• Other Factors: Changes in gastric emptying, GI blood flow, and various physiologic factors.

Drug Distribution

Nonlinearity in distribution at high doses is usually caused by:

1. Saturation of Plasma Protein Binding Sites:     * Examples: Phenylbutazone and naproxen.     * There is a finite number of binding sites. As concentration increases, the fraction of unbound (free) drug increases.     * Effect on Parameters: Apparent volume of distribution ($V_d$) increases.

2. Saturation of Tissue Binding Sites:     * Examples: Thiopental and fentanyl.     * Saturation occurs with large single bolus doses or multiple dosing.     * Effect on Parameters: Apparent volume of distribution ($V_d$) decreases.

• Impact on Clearance ($Cl$):     * For drugs with a high Extraction Ratio ($ER$), clearance is greatly increased due to the saturation of binding sites.     * For drugs with a low $ER$, unbound clearance is unaffected, but an increase in pharmacological response can be expected due to higher free drug concentration.

Drug Metabolism

Capacity-limited metabolism is the most clinically important form of nonlinearity because small dose changes can cause large variations in $C_{ss}$.

1. Enzyme/Cofactor Saturation:     * Examples: Phenytoin, alcohol (ethanol), theophylline.     * Saturation results in decreased clearance ($Cl$) and increased $C_{ss}$.

2. Enzyme Induction:     * Example: Carbamazepine.     * Repetitive administration over time can lead to a decrease in peak plasma concentration due to autoinduction.     * Autoinduction is both dose- and time-dependent.     * Induction results in increased clearance ($Cl$) and decreased $C_{ss}$.

3. Other Metabolic Causes: Saturation of binding sites and inhibitory effects of metabolites on enzymes.

Drug Excretion

Two active renal processes are saturable:

1. Active Tubular Secretion:     * Example: Penicillin G.     * After the carrier system saturates, renal clearance decreases.

2. Active Tubular Reabsorption:     * Examples: Water-soluble vitamins and glucose.     * After the carrier system saturates, renal clearance increases.

3. Biliary Secretion:     * This is an active process subject to saturation.     * Examples: Tetracycline and indomethacin.

4. Other Renal Sources: Forced diuresis, changes in urine pH, nephrotoxicity, and saturation of binding sites.

Michaelis-Menten Equation

The kinetics of capacity-limited or saturable processes is described by the Michaelis-Menten equation:

$\frac{-dC}{dt} = \frac{V_{max} \times C}{K_m + C}$

• Definitions:     * $\frac{-dC}{dt}$: Rate of decline of drug concentration with time.     * $V_{max}$: Theoretical maximum rate of the process.     * $K_m$: Michaelis constant.

Three Kinetic Situations Based on $K_m$ and $C$:

1. When $K_m = C$:     * The equation becomes: $\frac{-dC}{dt} = \frac{V_{max}}{2}$     * The rate of the process is equal to exactly one-half of its maximum rate.

2. When $K_m \gg C$ (First-Order Kinetics):     * In this case, $K_m + C \approx K_m$.     * The equation simplifies to: $\frac{-dC}{dt} = \frac{V_{max} \times C}{K_m}$     * This is identical to the first-order elimination equation where $\frac{V_{max}}{K_m} = K_E$.     * Most drugs at usual dosage regimens stay well below their $K_m$ value, with exceptions like phenytoin and alcohol.

3. When $K_m \ll C$ (Zero-Order Kinetics):     * In this case, $K_m + C \approx C$.     * The equation simplifies to: $\frac{-dC}{dt} = V_{max}$     * The process occurs at a constant rate ($V_{max}$) independent of drug concentration (e.g., metabolism of ethanol).

• Combined Plot: A plot of elimination rate ($\frac{-dC}{dt}$) versus concentration ($C$) shows:     * Linear/First-order rate at low doses ($C \ll K_m$).     * Mixed-order rate at intermediate doses.     * Zero-order rate at high doses ($C \gg K_m$).

Estimation of Michaelis-Menten Parameters

Assumptions for Assessment

• The drug follows one-compartment kinetics.

• Elimination involves only a single capacity-limited process.

• Parameters can be assessed from plasma concentration-time data after i.v. bolus administration.

Estimation from Steady-State Concentration ($C_{ss}$)

When a drug is administered as a constant rate i.v. infusion or a multiple-dose regimen, the steady-state concentration is related to the dosing rate ($DR$):

$DR = C_{ss} \times Cl$

• Dosing Rate ($DR$) Definitions:     * $DR = R_0$ for zero-order i.v. infusion.     * $DR = \frac{F \times X_0}{\tau}$ for multiple oral dosage regimens ($X_0$ = oral dose, $\tau$ = dosing interval).

• Steady-State Michaelis-Menten Relationship: At steady-state, the dosing rate equals the rate of elimination:

$DR = \frac{V_{max} \times C_{ss}}{K_m + C_{ss}}$

• Hockey-Stick Curve: A plot of $C_{ss}$ versus $DR$ yields a typical "hockey-stick" shaped curve. Accurately defining this curve requires several steady-state measurements at different doses.

Graphical Methods for Estimating $K_m$ and $V_{max}$

1. Lineweaver-Burke Plot (Klotz Plot)

Rearranging the Michaelis-Menten steady-state equation into a double-reciprocal form:

$\frac{1}{DR} = \frac{K_m}{V_{max} \times C_{ss}} + \frac{1}{V_{max}}$

• Plot: Plotting $\frac{1}{DR}$ versus $\frac{1}{C_{ss}}$ yields a straight line.

• Slope: $\frac{K_m}{V_{max}}$

• Y-intercept: $\frac{1}{V_{max}}$

2. Direct Linear Plot

• This method uses pairs of $C_{ss}$ values ($C_{ss,1}$ and $C_{ss,2}$) obtained at two different dosing rates ($DR_1$ and $DR_2$).

• Graphing Procedure:     1. The point ($C_{ss,1}$, $DR_1$) is marked and joined to form a line.     2. A second line is formed by joining ($C_{ss,2}$, $DR_2$).     3. The intersection point of these two lines is extrapolated to the axes.     4. The intersection extrapolated to the Y-axis (Dosing Rate axis) gives $V_{max}$.     5. The intersection extrapolated to the X-axis (Concentration axis) gives $K_m$.

3. DR versus DR/Css Plot

Rearranging the equation to a different linear form:

$DR = V_{max} - \frac{K_m \times DR}{C_{ss}}$

• Plot: Plotting $DR$ versus $\frac{DR}{C_{ss}}$ yields a straight line.

• Slope: $-K_m$

• Y-intercept: $V_{max}$

Limitations of Parameter Estimation

The assumptions of a one-compartment system and a single capacity-limited process are often oversimplified. Estimates for $K_m$ and $V_{max}$ will usually be larger and equations more complex if:

1. The drug is eliminated by more than one capacity-limited process.

2. The drug exhibits parallel capacity-limited and first-order elimination processes.

3. The drug follows a multicompartment pharmacokinetic model.